PMID: 590303Nov 14, 1977

Pharmacokinetics of atenolol in patients with renal impairment

European Journal of Clinical Pharmacology
J SassardP Y Zech

Abstract

The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive patients with widely differing levels of renal impairment. In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses. This value increased markedly in patients with renal insufficiency and the blood clearance of atenolol was found to have a significant correlation with the glomerular filtration rate. This demonstrated the importance of the kidneys in the elimination of the drug. After 8 weeks oral treatment with atenolol (100 mg twice daily) a significant decrease in blood pressure, heart rate and plasma renin activity was observed, but no correlation was established between the blood levels of atenolol and any of its pharmacodynamic effects. A positive correlation was found however between the anti-hypertensive action of atenolol and the pretreatment value of the plasma renin activity.

References

Nov 1, 1976·Clinical Pharmacology and Therapeutics·H C BrownR G Shanks
Jun 1, 1975·The Journal of Pharmacy and Pharmacology·B Scales, P B Copsey
Jun 1, 1977·Clinical Pharmacology and Therapeutics·A AmeryT Reybrouck
Apr 1, 1976·The New England Journal of Medicine·H Yazici
Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Apr 1, 1976·British Journal of Clinical Pharmacology·T B TjandramagaP J Schepper
Jun 1, 1975·Journal of Pharmacokinetics and Biopharmaceutics·E E Ohnhaus, P Spring
Dec 19, 1975·European Journal of Clinical Pharmacology·S Oie, G Levy
Jan 1, 1976·The Journal of Clinical Endocrinology and Metabolism·J SassardC A Bizollon
Apr 1, 1973·The Journal of Clinical Investigation·G BodemC A Chidsey
Dec 16, 1974·JAMA : the Journal of the American Medical Association·W M BennettC J Coggins
Jan 1, 1973·Clinical Pharmacology and Therapeutics·G Bodem, C A Chidsey
Nov 1, 1974·Clinical Pharmacology and Therapeutics·D T LowenthalW J Cirksena
May 1, 1973·British Heart Journal·P A MajidS H Taylor
Jul 26, 1974·European Journal of Clinical Pharmacology·G BodemR Gugler
May 20, 1972·British Medical Journal·F D ThompsonD M Foulkes

Citations

Jan 1, 1981·European Journal of Clinical Pharmacology·W KirchM Schäfer
May 1, 1980·European Journal of Clinical Pharmacology·E RivaJ McAinsh
Oct 1, 1980·European Journal of Clinical Pharmacology·G BerglundJ A Thomis
May 17, 1978·European Journal of Clinical Pharmacology·J D FitzgeraldJ McAinsh
Jan 1, 1982·European Journal of Drug Metabolism and Pharmacokinetics·W Kirch, K G Görg
Jan 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·A CelardoM Bonati
Jun 1, 1979·British Journal of Clinical Pharmacology·S H WanR F Maronde
Jan 1, 1979·British Journal of Clinical Pharmacology·R A VukovichA Darragh
Jul 1, 1991·British Journal of Clinical Pharmacology·N FerryJ Sassard
Dec 4, 1982·British Medical Journal·A B Shaw, S K Gopalka
Apr 1, 1986·Journal of Pharmacological Methods·G L TrainaM Bonati
Aug 1, 1991·The Journal of Pharmacy and Pharmacology·P AgonJ M Kaufman
Jan 1, 1989·European Journal of Clinical Pharmacology·N A MintonJ A Henry
Jan 1, 1985·European Journal of Clinical Pharmacology·C ThuillezJ F Giudicelli
Jul 21, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·G A AllanR Webster
Jan 26, 2013·Hemodialysis International·Shih-Han S HuangRita S Suri
Apr 1, 1980·British Journal of Clinical Pharmacology·B FlouvatA Baglin
Jun 1, 1980·British Journal of Clinical Pharmacology·H J Waal-Manning, P Bolli
Mar 1, 1988·British Journal of Clinical Pharmacology·M ScottT J Fitzsimons
Jul 1, 1985·Journal of Clinical Pharmacology·V M CampeseS G Massry
Apr 1, 1983·Journal of Clinical Pharmacology·W KirchW Braun
Nov 10, 1983·The American Journal of Cardiology·M J Kendall
Jun 4, 2013·The Journal of Emergency Medicine·Nathan R HootKenneth H Palm
May 1, 1986·Biopharmaceutics & Drug Disposition·J McAinshJ Young
Jan 1, 1983·Biopharmaceutics & Drug Disposition·W KirchE Mutschler
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·C G Regårdh
Nov 19, 2020·Journal of Clinical Pharmacology·Paul R V MalikAndrea N Edginton

Related Concepts

Tenormin
Diastolic Blood Pressure
Pulse Rate
Hypertensive Disease
Kidney Diseases
Propanolamines
Preprorenin

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
P R ReevesM J Winrow
Journal of Pharmacokinetics and Biopharmaceutics
G L Traina, M Bonati
© 2021 Meta ULC. All rights reserved